Registered Nurse in Spencer, IA Accepting Medicare

6 Registered Nurse nurses found. Showing 1 - 6

Robert Matthew Baltes, MSN, ARNP, PMHNP-BC Registered Nurse - Addiction (Substance Use Disorder) Medicare: Accepting Medicare Assignments Practice Location: 1200 1st Ave E Ste 1, Spencer, IA 51301 Phone: 515-364-6198

Mrs. Patricia J Hansen, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1200 1st Ave E, Ste C, Spencer, IA 51301 Phone: 712-262-7511    Fax: 712-262-3658

Deanne Sue Hoger, MSN, RN CNL Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1200 1st Ave E, Spencer, IA 51301 Phone: 712-264-8649    Fax: 712-264-8572

Mrs. Morgan Elizabeth Spielman, Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 116 E 11th St Ste 101, Spencer, IA 51301 Phone: 712-264-3500

Mr. Scott Alan Goehring, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1200 1st Ave E, Ste C, Spencer, IA 51301 Phone: 712-262-7511    Fax: 712-262-3658

Daniel Westphal, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1502 W 12th St, Spencer, IA 51301 Phone: 712-363-7490

News Archive

American HomePatient signs fourth forbearance agreement

American HomePatient, Inc. (OTCBB: AHOM), one of the nation's largest home health care providers, today announced that it has entered into a fourth forbearance agreement with NexBank, SSB, the agent for its senior debt (the "Agent"), and the holders in interest of a majority of the senior debt (the "Forbearance Holders").

New comprehensive trademark search capabilities available for pharmaceutical industry

CT Corsearch, part of CT, a Wolters Kluwer business and the premier provider of clearance and protection solutions for trademark and brand professionals, today announced the availability of its new comprehensive trademark search capabilities designed specifically for the specialized needs of the pharmaceutical industry.

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.

Advance care planning often fails to communicate patient's preferences

Too few older adults plan ahead for end-of-life medical decisions. Even when they do identify a loved one to make decisions for them, their preferences are not always communicated or understood, according to a new study led by a Yale researcher.

Read more Medical News

› Verified 3 days ago